Testing effectiveness (Phase 2)Not Yet RecruitingNCT07054242
What this trial is testing
A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvant Treatment of Triple-Negative Breast Cancer (TNBC)
Who this might be right for
Neoadjuvant TherapyStage II to III (T1cN1-2 or T2-4N0-2) TNBC Breast Cancer
Yantai Yuhuangding Hospital 52